Charles River Laboratories International Dirección
Dirección controles de criterios 4/4
El CEO de Charles River Laboratories International's es Jim Foster , nombrado en Jan 1991, tiene una permanencia de 33.25 años. compensación anual total es $14.10M, compuesta por 10.4% salario y 89.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.51% de las acciones de la empresa, por valor de $61.02M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 10 años, respectivamente.
Información clave
Jim Foster
Chief Executive Officer (CEO)
US$14.1m
Compensación total
| Porcentaje del salario del CEO | 10.4% |
| Permanencia del CEO | 33.3yrs |
| Participación del CEO | 0.5% |
| Permanencia media de la dirección | 4.5yrs |
| Promedio de permanencia en la Junta Directiva | 10.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Charles River Laboratories International: A Great Business At A Decent Price
Feb 06Charles River acquires SAMDI Tech for $50M in cash
Jan 30Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?
Jan 24If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity
Jan 10Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital
Jan 05We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Dec 14Charles River Laboratories Non-GAAP EPS of $2.63 beats by $0.13, revenue of $989.2M beats by $18.77M, updates FY guidance
Nov 02Charles River Laboratories: Near-Term Headwinds Outweigh Long-Term Tailwinds
Oct 18Are Investors Undervaluing Charles River Laboratories International, Inc. (NYSE:CRL) By 21%?
Oct 18Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Oct 04Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 30 2023 | n/a | n/a | US$475m |
| Sep 30 2023 | n/a | n/a | US$475m |
| Jul 01 2023 | n/a | n/a | US$484m |
| Apr 01 2023 | n/a | n/a | US$496m |
| Dec 31 2022 | US$13m | US$1m | US$486m |
| Sep 24 2022 | n/a | n/a | US$436m |
| Jun 25 2022 | n/a | n/a | US$443m |
| Mar 26 2022 | n/a | n/a | US$422m |
| Dec 25 2021 | US$14m | US$1m | US$391m |
| Sep 25 2021 | n/a | n/a | US$397m |
| Jun 26 2021 | n/a | n/a | US$396m |
| Mar 27 2021 | n/a | n/a | US$375m |
| Dec 26 2020 | US$13m | US$1m | US$364m |
| Sep 26 2020 | n/a | n/a | US$301m |
| Jun 27 2020 | n/a | n/a | US$271m |
| Mar 28 2020 | n/a | n/a | US$248m |
| Dec 28 2019 | US$18m | US$1m | US$252m |
| Sep 28 2019 | n/a | n/a | US$231m |
| Jun 29 2019 | n/a | n/a | US$219m |
| Mar 30 2019 | n/a | n/a | US$227m |
| Dec 29 2018 | US$14m | US$1m | US$225m |
| Sep 29 2018 | n/a | n/a | US$135m |
| Jun 30 2018 | n/a | n/a | US$128m |
| Mar 31 2018 | n/a | n/a | US$129m |
| Dec 30 2017 | US$13m | US$1m | US$123m |
Compensación vs. Mercado: La compensación total ($USD14.10M) de Jim está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD13.51M).
Compensación vs. Ingresos: La compensación de Jim ha sido consistente con los resultados de la empresa en el último año.
CEO
Jim Foster (72 yo)
33.3yrs
Permanencia
US$14,096,923
Compensación
Mr. James C. Foster, J.D. has been the Chairman of the Board at Charles River Laboratories, Inc. (CRL) since 2000 and has been its Chief Executive Officer since 1992 and serves as its President since 1991....
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Chairman | 33.3yrs | US$14.10m | 0.51% $ 60.1m | |
| Corporate Executive VP & CFO | 2yrs | US$3.81m | 0.00053% $ 62.3k | |
| Corporate Executive VP & COO | 2.5yrs | US$4.99m | 0.080% $ 9.4m | |
| Corporate Executive Vice President of Corporate Development & Strategy | 13.3yrs | US$3.06m | 0.026% $ 3.0m | |
| Corporate Executive Vice President of Community Relations | 7.6yrs | US$2.91m | 0.044% $ 5.2m | |
| Corporate Senior VP & Chief Accounting Officer | 7.1yrs | sin datos | 0.0081% $ 956.0k | |
| Corporate Senior VP & Chief Scientific Officer | 2.5yrs | sin datos | sin datos | |
| Corporate Senior VP & Chief Information Officer | 2.9yrs | sin datos | sin datos | |
| Corporate Vice President of Investor Relations | no data | sin datos | sin datos | |
| Corporate Senior VP | 3.7yrs | sin datos | sin datos | |
| Corporate Vice President & Chief Communications Officer | no data | sin datos | sin datos | |
| Corporate Executive VP & Chief People Officer | 5.3yrs | sin datos | 0.018% $ 2.2m |
4.5yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CRL se considera experimentado (4.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Chairman | 35.3yrs | US$14.10m | 0.51% $ 60.1m | |
| Independent Director | 16.4yrs | US$341.02k | 0.13% $ 14.8m | |
| Independent Director | 13.3yrs | US$339.77k | 0.045% $ 5.2m | |
| Lead Independent Director | 21.3yrs | US$371.02k | 0.0097% $ 1.1m | |
| Independent Director | 4.6yrs | US$346.02k | 0.0053% $ 627.9k | |
| Independent Director | 13.3yrs | US$346.02k | 0.060% $ 7.0m | |
| Independent Director | 1.4yrs | US$437.78k | 0.00048% $ 56.4k | |
| Director | 6.8yrs | US$336.02k | 0.020% $ 2.4m | |
| Independent Director | 15.6yrs | US$339.77k | 0.014% $ 1.7m | |
| Independent Director | 4.3yrs | US$339.77k | 0.0035% $ 411.6k | |
| Independent Director | 3.6yrs | US$324.77k | 0.0035% $ 416.3k | |
| Independent Director | less than a year | sin datos | 0% $ 0 |
10.1yrs
Permanencia media
67.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de CRL son experimentados ( 10 años antigüedad media).